Neil Herskowitz Biography and Net Worth

Director of Avenue Therapeutics


Mr. Herskowitz joined our Board of Directors in December 2015. Mr. Herskowitz has served as the managing member of the ReGen Group of companies, located in New York, since 1998, which include ReGen Capital Investments LLC and Riverside Claims Investments LLC. He has also served as the President of its affiliate, Riverside Claims LLC, since June 2004.  He also serves as Chairman of the board of directors of Starting Point Services for Children, a not-for-profit corporation. Mr. Herskowitz received a B.B.A. in Finance from Bernard M. Baruch College in 1978.

How do I contact Neil Herskowitz?

The corporate mailing address for Mr. Herskowitz and other Avenue Therapeutics executives is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. Avenue Therapeutics can also be reached via phone at (781) 652-4500 and via email at [email protected]. Learn More on Neil Herskowitz's contact information.

Has Neil Herskowitz been buying or selling shares of Avenue Therapeutics?

Neil Herskowitz has not been actively trading shares of Avenue Therapeutics over the course of the past ninety days. Most recently, on Thursday, May 6th, Neil Herskowitz bought 2,500 shares of Avenue Therapeutics stock. The stock was acquired at an average cost of $3.99 per share, with a total value of $9,975.00. Learn More on Neil Herskowitz's trading history.

Who are Avenue Therapeutics' active insiders?

Avenue Therapeutics' insider roster includes Neil Herskowitz (Director), and Joseph Vazzano (CFO). Learn More on Avenue Therapeutics' active insiders.

Are insiders buying or selling shares of Avenue Therapeutics?

During the last twelve months, Avenue Therapeutics insiders bought shares 2 times. They purchased a total of 767,085 shares worth more than $552,301.20. The most recent insider tranaction occured on September, 8th when Director Lindsay A Md Rosenwald bought 348,675 shares worth more than $251,046.00. Insiders at Avenue Therapeutics own 1.8% of the company. Learn More about insider trades at Avenue Therapeutics.

Information on this page was last updated on 9/8/2023.

Neil Herskowitz Insider Trading History at Avenue Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/6/2021Buy2,500$3.99$9,975.00View SEC Filing Icon  
5/6/2021Buy2,500$3.99$9,975.00View SEC Filing Icon  
2/27/2020Buy2,400$8.20$19,680.00View SEC Filing Icon  
2/25/2020Buy10,000$8.98$89,800.00View SEC Filing Icon  
6/18/2019Buy5,000$5.86$29,300.00View SEC Filing Icon  
4/15/2019Buy1,000$4.52$4,520.00View SEC Filing Icon  
3/28/2019Buy600$5.11$3,066.00View SEC Filing Icon  
2/25/2019Buy5,000$5.46$27,300.00View SEC Filing Icon  
2/5/2019Buy8,850$5.88$52,038.00View SEC Filing Icon  
1/30/2019Buy650$5.91$3,841.50View SEC Filing Icon  
1/28/2019Buy1,447$5.84$8,450.48View SEC Filing Icon  
4/25/2018Buy1,000$3.80$3,800.00View SEC Filing Icon  
10/17/2017Buy1,000$5.01$5,010.00View SEC Filing Icon  
10/9/2017Buy500$5.24$2,620.00View SEC Filing Icon  
See Full Table

Neil Herskowitz Buying and Selling Activity at Avenue Therapeutics

This chart shows Neil Herskowitz's buying and selling at Avenue Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Avenue Therapeutics Company Overview

Avenue Therapeutics logo
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.
Read More

Today's Range

Now: $0.15
Low: $0.15
High: $0.16

50 Day Range

MA: $0.15
Low: $0.12
High: $0.19

2 Week Range

Now: $0.15
Low: $0.11
High: $1.36

Volume

786,507 shs

Average Volume

5,469,244 shs

Market Capitalization

$6.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A